Comparative Pharmacology
Head-to-head clinical analysis: RENVELA versus SEVELAMER HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENVELA versus SEVELAMER HYDROCHLORIDE.
RENVELA vs SEVELAMER HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Renvela (sevelamer carbonate) is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, inhibiting phosphate absorption and reducing serum phosphate levels. It also binds bile acids, leading to decreased LDL cholesterol.
Sevelamer hydrochloride is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and thereby reducing serum phosphate levels.
Adults: 800 mg orally three times daily with meals; titrate based on serum phosphorus levels up to 2400 mg per meal (7200 mg/day maximum).
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 800 mg per meal at 2-week intervals based on serum phosphorus levels. Maintenance: typically 2.4-4.8 g/day divided with meals.
None Documented
None Documented
Not applicable as sevelamer is not absorbed. No systemic half-life; local gastrointestinal transit time is approximately 3-4 hours.
Not applicable; sevelamer is not absorbed. The polymer acts locally in the gastrointestinal tract and does not have a measurable plasma half-life.
Sevelamer carbonate is not absorbed systemically; excretion is entirely fecal as the parent compound. Less than 0.01% is absorbed and excreted renally.
Sevelamer hydrochloride is not absorbed systemically; it is eliminated entirely in the feces as the unchanged polymer. No renal or biliary elimination occurs.
Category C
Category A/B
Phosphate Binder
Phosphate Binder